MX2023013912A - Metodos para inhibir ras. - Google Patents
Metodos para inhibir ras.Info
- Publication number
- MX2023013912A MX2023013912A MX2023013912A MX2023013912A MX2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A MX 2023013912 A MX2023013912 A MX 2023013912A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inhibiting ras
- inhibiting
- ras
- disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La divulgación presenta métodos para inhibir las proteínas RAS. La divulgación también contiene métodos para el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192837P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030823 WO2022251292A1 (en) | 2021-05-25 | 2022-05-25 | Methods for inhibiting ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013912A true MX2023013912A (es) | 2024-02-12 |
Family
ID=82115695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013912A MX2023013912A (es) | 2021-05-25 | 2022-05-25 | Metodos para inhibir ras. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277796A1 (es) |
| EP (1) | EP4346898A1 (es) |
| JP (1) | JP2024521774A (es) |
| KR (1) | KR20240026526A (es) |
| CN (2) | CN117715658A (es) |
| AU (1) | AU2022281343A1 (es) |
| CA (1) | CA3219533A1 (es) |
| IL (1) | IL308771A (es) |
| MX (1) | MX2023013912A (es) |
| TW (1) | TW202313631A (es) |
| WO (1) | WO2022251292A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120988055A (zh) | 2019-11-04 | 2025-11-21 | 锐新医药公司 | Ras抑制剂 |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| TW202309053A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| AU2023204824A1 (en) * | 2022-01-10 | 2024-07-18 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119301132A (zh) * | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| JP2025532258A (ja) | 2022-09-29 | 2025-09-29 | グアンチョウ ジョーヨー ファーマテック シーオー．，エルティーディー | 大環状誘導体及びその使用 |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| EP4687905A1 (en) * | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202446387A (zh) * | 2023-04-06 | 2024-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療癌症之三環化合物 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025019318A2 (en) * | 2023-07-14 | 2025-01-23 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| CN119431325A (zh) * | 2024-10-31 | 2025-02-14 | 诚达药业股份有限公司 | 一种3-（1h-吡唑-1-基）氮杂环丁烷类化合物及其合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020132597A1 (en) | 2018-12-21 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| DE102019122206B4 (de) | 2019-08-19 | 2021-07-08 | Webasto SE | Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120988055A (zh) | 2019-11-04 | 2025-11-21 | 锐新医药公司 | Ras抑制剂 |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
-
2022
- 2022-05-25 CA CA3219533A patent/CA3219533A1/en active Pending
- 2022-05-25 JP JP2023572737A patent/JP2024521774A/ja active Pending
- 2022-05-25 KR KR1020237044138A patent/KR20240026526A/ko active Pending
- 2022-05-25 TW TW111119516A patent/TW202313631A/zh unknown
- 2022-05-25 AU AU2022281343A patent/AU2022281343A1/en active Pending
- 2022-05-25 EP EP22731928.2A patent/EP4346898A1/en active Pending
- 2022-05-25 WO PCT/US2022/030823 patent/WO2022251292A1/en not_active Ceased
- 2022-05-25 IL IL308771A patent/IL308771A/en unknown
- 2022-05-25 CN CN202280050079.1A patent/CN117715658A/zh active Pending
- 2022-05-25 CN CN202410561373.XA patent/CN118557730A/zh active Pending
- 2022-05-25 MX MX2023013912A patent/MX2023013912A/es unknown
-
2023
- 2023-11-22 US US18/518,027 patent/US20240277796A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240026526A (ko) | 2024-02-28 |
| AU2022281343A1 (en) | 2023-11-30 |
| EP4346898A1 (en) | 2024-04-10 |
| CN117715658A (zh) | 2024-03-15 |
| JP2024521774A (ja) | 2024-06-04 |
| WO2022251292A1 (en) | 2022-12-01 |
| IL308771A (en) | 2024-01-01 |
| TW202313631A (zh) | 2023-04-01 |
| CN118557730A (zh) | 2024-08-30 |
| US20240277796A1 (en) | 2024-08-22 |
| CA3219533A1 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013912A (es) | Metodos para inhibir ras. | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| PH12021553000A1 (en) | Multispecific proteins | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX2024003713A (es) | Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3). | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| AU2018301696A8 (en) | Heterocyclic inhibitors of ATR kinase | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| AU2018284249A1 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof |